Shed vs Willow: Which GLP-1 Provider Is Better?

By Iacob Pastina, Independent Researcher

48 providers verified independently·Independent research·How we rank →

Willow beats Shed overall, scoring 8.2/10 vs 7.8/10. Shed is more affordable at $199/mo vs $299/mo. Choose Shed for users who want fast delivery and a streamlined compounded gl. Choose Willow for users who want comprehensive clinical support with flexibili.

A side-by-side comparison of Shed and Willow covering pricing, scores, medication types, insurance, and more to help you decide.

Shed

#17 of 48

7.8/10

Newer GLP-1 provider focused on speed and simplicity — fast approvals, fast shipping, and a clean user experience at a competitive price point.

Visit Shed

Higher Rated

Willow

#8 of 48

8.2/10

Personalized GLP-1 weight loss with ongoing clinical support. Compounded semaglutide and tirzepatide only — Willow explicitly does not prescribe brand-name Wegovy or Zepbound. Added oral compounded semaglutide tablets as a non-injectable option.

Visit Willow

Feature	Shed	Willow
Our Score	7.8/10	8.2/10
Starting Price	$199/mo	$299/mo
Medication Type	Both	Compounded
Insurance Accepted	No	No
Best For	Users who want fast delivery and a streamlined compounded GLP-1 experience	Users who want comprehensive clinical support with flexibility between injectable and oral compounded semaglutide routes
Ranking	#17	#8

Pros & Cons Compared

Shed

Pros

+Industry-leading delivery speed — most patients receive medication within 2-3 days of enrollment
+$149/mo is competitively priced for an all-inclusive compounded program with good support
+Streamlined onboarding with no video call — approved and shipped faster than most competitors
+Clean, modern UX with real-time shipping tracking and easy provider messaging

Cons

−Compounded semaglutide and tirzepatide only — no brand-name options
−Newer company (founded 2024) with limited track record and outcome data
−No insurance billing and no FSA/HSA superbills currently available
−Clinical support is responsive but less proactive than premium platforms

Willow

Pros

+Includes monthly provider check-ins and dose adjustments at no extra cost
+Offers both injectable AND oral compounded semaglutide — one of few platforms with a daily oral tablet option
+$299/mo all-in for compounded semaglutide with monthly provider support
+90%+ patient retention rate after 3 months per their published outcomes data

Cons

−Compounded-only — no brand-name Wegovy or Zepbound through the platform
−Tirzepatide pricing reaches $499-$524 at higher doses — starting dose is $399/mo
−Cash-pay only — no insurance billing, though they provide superbills for FSA/HSA
−Founded in 2024 — less track record than Ro or Hims, though growth has been fast

Our Verdict

Willow edges out Shed with a score of 8.2/10 vs 7.8/10. If budget is your priority, Shed starts at $199/mo compared to Willow's $299/mo. Shed offers both brand-name and compounded medications, giving you more flexibility. Choose Shed if you want: users who want fast delivery and a streamlined compounded glp-1 experience. Choose Willow if you want: users who want comprehensive clinical support with flexibility between injectable and oral compounded semaglutide routes.

Still undecided? Editor's #1 Overall Pick

Embody

$299/mo · 7.3/10 · Compounded

If neither Shed nor Willow feels like the right fit, our overall #1 pick across all 48 GLP-1 telehealth providers is Embody — strongest balance of clinical oversight, transparent pricing, and verified availability.

Visit Embody→Read our full Embody review